Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

NCT04962009 | Completed Results

• 1 other identifier: TGLA-2021-01
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This is a pilot, open-label, multi-center clinical study. Each potential subject that has met all screening inclusion/exclusion criteria will undergo a six-week washout phase where they will discontinue the use of their topical hypotensive medication. After the six-week washout, each potential subject will return for a baseline visit. Investigators will verify that a potential subject has discontinued the use of their topical hypotensive medication(s) and all their prohibited systemic medications for the last 6 weeks. In addition, each subject will have discontinued the use of all other ocular drops, gels or ointments 24 hours prior to the visit (Visit 2) and continues to meet all screening and washout criteria. After completing the baseline examination, each potential subject that meet all baseline inclusion/exclusion for the treatment phase of the study will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.

Conditions

Elevated Intraocular Pressure (IOP)

Outcome Measures

Primary Outcomes (1)

• Mean Percent Intraocular Pressure (IOP) Change

  Mean percent change in Intraocular Pressure (IOP) from baseline to days 90

  day 90

Study Arms (1)

Travoprost Evolute® (Travoprost Punctal Plug Delivery System, T-PPDS), 166 ug

EXPERIMENTAL

Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.

Combination Product: Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug

Interventions

Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug COMBINATION_PRODUCT

Each subject will have his/her lower puncta of each eye inserted with a Travoprost Evolute®. Each study subject will be instructed to return to the investigator's office the next day, 7, 28, 60 and 90-days after the insertion of their plugs for follow-up examinations.

Travoprost Evolute® (Travoprost Punctal Plug Delivery System, T-PPDS), 166 ug

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subject, 18 years of age or older at the time of the screening examination and has been diagnosed with bilateral OAG or OH
• A subject must be able and willing to read, comprehend and give authorization for Use/Disclosure of Health Information (HIPAA) and informed consent
• A subject must not have taken any ocular hypertension medication(s) within the last 12 hours of the screening visit unless in the opinion of the screening physician it poses an undue risk.
• A subject must be willing to have the lower puncta of each eye inserted with a study plug
• A subject's screening visit (pre-washout) Intraocular Pressures (IOPs), measured between 8:00 and 10:00 AM, is less than 22 mmHg in both eyes
• A subject Intraocular Pressures (IOPs) are currently controlled (\< 22 mm Hg) with a topical prostaglandin or in conjunction with one other topical ocular hypotensive drug, not including any fixed-combination formulations (i.e., Cosopt, Combigan, Azarga, etc.), in both eyes for at least one month
• A subject has a Best-Corrected Distance (Glasses), pinhole visual acuity of 20/100 (Snellen) or better in both eyes
• A subject has documented perimetry results within the last 6 months prior to the Screening Visit for both eyes NOTE: If perimetry measurement are older than 6 months, perform automated perimetry at the screening visit

You may not qualify if:

• A subject with a history of non-response to topical prostaglandin eye drops for OAG/OH
• A subject with angle-closure glaucoma, neovascular glaucoma, traumatic glaucoma or iridocorneal endothelium syndrome in either eye
• A subject with a known sensitivity to travoprost, fluorescein, topical anesthetic, silicone, any inactive ingredient of the Travoprost Evolute® or any other products required for study procedures
• A subject with a history of complications, AEs, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye
• A subject with a history of intolerance to punctal plugs or a known sensitivity to any inactive ingredient of the punctal plug, silicone, topical anesthetic, or any other products required for the study
• A subject with structural lid abnormalities (i.e., ectropion, entropion) in either eye
• A subject with an active lid disease in either eye (i.e., moderate or severe blepharitis, meibomianitis) that requires medical treatment
• A subject with any clinically significant (moderate or severe) lid, conjunctival or corneal findings in either eye at the screening visit
• A subject with a history of chronic/recurrent inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye
• A subject who would require the use of any ocular medication(s), an over-the-counter drop(s), ointment(s) or gel(s), other than the study hypotensive medication(s) in either eye during the study period
• A subject who has had any ophthalmic surgical procedures (i.e., glaucoma laser, minimally invasive glaucoma surgery, cataract, refractive, etc.) in either eye within the last six months or will require ophthalmic surgery before completing the study
• A subject with a history of penetrating keratoplasty in either eye
• A subject requiring the use of a contact lens in either eye at any time during the study period
• A subject with advanced diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion in either eye
• A subject with a history of macular edema in either eye

Sponsors & Collaborators

• Mati Therapeutics Inc.: lead

Study Sites (1)

Stiles Eyecare Excellence

Overland Park, Kansas, 66213, United States

Location

MeSH Terms

Conditions

Ocular Hypertension

Condition Hierarchy (Ancestors)

Eye Diseases

Results Point of Contact

• Title: Deepank Utkhede
• Organization: Mati Therapeutics Inc.

dutkhede@matitherapeutics.com

778-991-3301

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Travoprost Evolute (Travoprost Punctal Plug Delivery System), 166 ug

Study Record Dates

• First Submitted: July 5, 2021
• First Posted: July 14, 2021
• Study Start: September 8, 2021
• Primary Completion: July 15, 2022
• Study Completion: July 15, 2022
• Last Updated: September 13, 2023
• Results First Posted: September 13, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)